ClinicalTrials.gg
TerminatedNCT04497948Updated Nov 17, 2021Results posted

Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19

A Phase 1 interventional study of Acalabrutinib in COVID-19, sponsored by Acerta Pharma BV. Terminated at 4 sites in Brazil. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-11-17.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Why this study was terminated
Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19 did not meet their primary efficacy endpoints. Based on this higher management made the decision to prematurely terminate the D822FC00005 PK study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in COVID-19 by AstraZeneca — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · AstraZeneca.

Enrollment
25th of 26
9 · median 147
Started
2020
with 11 others
Phase 1
9 of 43
none open now
Registered
5th of 43
by date

Among the 43 studies in COVID-19 by AstraZeneca, this one is the 25th largest by enrollment of the 26 interventional ones that give a count, is one of 12 that started in 2020, is one of 9 in phase 1, and was the 5th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 43 studies in COVID-19 by AstraZeneca is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in COVID-19 by AstraZeneca, or all of them as a file.
02

Study summary

Study D822FC00005 will investigate the Phamacokinetics, Safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.

Read the detailed description

This study is to support the ongoing clinical development of acalabrutinib (CALQUENCE®) in hospitalized COVID-19 patients. Because many COVID-19 patients may be unable to swallow capsules due to respiratory failure (eg, they may require endotracheal intubation for ventilator support and Naso Gastric tube placement), it is important to have a clinically acceptable method to administer acalabrutinib (capsules) via NG tube. Furthermore, many hospitalized patients are placed on high doses of proton pump inhibitors (PPIs) (also commonly known as antacid medication). This study is designed to determine the Pharmaco Kinetics (effect of body/ bodily systems on the drug), safety and tolerability of acalabrutinib suspension, when coadministered with a PPI, in participants with confirmed SARS-CoV-2 infection requiring hospitalization due to respiratory failure, attributable to COVID-19 pneumonia and who have an Nasogastric (NG) tube in place.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • 2019 novel coronavirus disease
  • Acalabrutinib
  • Btk inhibitor
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant or legally authorized representative must be able to understand the purpose and risks of the study and provide written and authorization to use protected health information (in accordance with national and local patient privacy regulations).
  2. Participants who are hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by PCR test or other commercial or public health assay in any specimen, as documented by either of the following:

    1. PCR positive in sample collected \< 72 hours prior to first dose, OR
    2. PCR positive in sample collected ≥ 72 hours prior to first dose (but no more than 14 days prior to first dose), documented inability to obtain a repeat sample (eg, due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc), AND progressive disease suggestive of ongoing SARS-CoV-2 infection 3 Evidence of respiratory failure attributable to COVID-19 pneumonia (documented radiographically) before enrollment 4 Nasogastric tube or other types of oral or percutaneous gastric feeding tube; placement must be radiographically confirmed and expected to remain in place, as judged by the investigator, for a minimum of 3 days after study enrolment.

      5 Has received treatment with PPIs (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole) for a minimum of 24 hours immediately prior to enrollment; any PPI will be permitted, provided it meets the minimum equivalent daily dose of 20 mg rabeprazole.

Exclusion criteria

Exclusion Criteria:

  1. Any serious and uncorrectable medical condition or abnormality of clinical laboratory tests that, in the Investigator's judgment, precludes the participant's safe participation in and completion of the study.
  2. In the opinion of the Investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
  3. Current nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  4. Received BTK inhibitor within 7 days before enrollment.
  5. Requires or is receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days prior to enrollment. Other anticoagulants are permitted.
  6. Participants on dual antiplatelet and therapeutic anticoagulant therapy (eg, aspirin and therapeutic doses of low molecular weight heparin are not allowed; however, aspirin and prophylactic/ low doses of low-molecular-weight heprin are allowed).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Other
    Single Arm

    Single Arm

    Drug: Acalabrutinib

Interventions

  • Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor

    Also known as: CALQUENCE®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From 0 to 12 Hours (AUC12h) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2 (Day 2), and Visit 3 (Day 5)

    To summarize the PK parameter AUC12h of Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC + PPI

    Time frame: pre-dose and 0.5, 1, 2, 4, 6, and 12 hours in visit 1 on Day 1, visit 2 on Day 2 and visit 3 on Day 5

  2. Area Under the Concentration-time Curve From 0 to Time to Last Quantifiable Concentration (AUClast) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2 (Day 2), and Visit 3 (Day 5)

    To summarize the PK parameter AUClast for Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC +PPI

    Time frame: pre-dose and 0.5, 1, 2, 4, 6, and 12 hours in visit 1 on Day 1, visit 2 on Day 2 and visit 3 on Day5

  3. Maximum Observed Plasma Concentration (Cmax) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2(Day2) and Visit 3 (Day 5)

    To summarize the PK parameter Cmax of Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC +PPI

    Time frame: pre-dose and 0.5, 1, 2, 4, 6, and 12 hours in visit 1(Day 1), visit 2(Day 2) and visit 3(Day 5)

07

Results

Posted Nov 5, 2021

Participant flow

Approximately 20 participants were planned to be enrolled to have at least 16 evaluable participants.

Participant flow — Overall Study
MilestoneAcalabrutinib + BSC + PPI
Started9
Completed7
Not completed2
Withdrew: Death2

Outcome measures

PrimaryArea Under the Concentration-time Curve From 0 to 12 Hours (AUC12h) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2 (Day 2), and Visit 3 (Day 5)

To summarize the PK parameter AUC12h of Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC + PPI

Time frame:
pre-dose and 0.5, 1, 2, 4, 6, and 12 hours in visit 1 on Day 1, visit 2 on Day 2 and visit 3 on Day 5
Reported as:
Geometric mean · h·ng/mL
Area Under the Concentration-time Curve From 0 to 12 Hours (AUC12h) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2 (Day 2), and Visit 3 (Day 5)
h·ng/mLAcalabrutinib + BSC + PPI, Visit 1 on Day 1Acalabrutinib + BSC + PPI, Visit 2 on Day 2Acalabrutinib + BSC + PPI, Visit 3 on Day 5
Acalabrutinib524.7 ± 86.5496.5 ± 58.0201.1 ± 95.3
ACP-5862832.8 ± 29.31228.0 ± 35.1867.1 ± 43.1
PrimaryArea Under the Concentration-time Curve From 0 to Time to Last Quantifiable Concentration (AUClast) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2 (Day 2), and Visit 3 (Day 5)

To summarize the PK parameter AUClast for Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC +PPI

Time frame:
pre-dose and 0.5, 1, 2, 4, 6, and 12 hours in visit 1 on Day 1, visit 2 on Day 2 and visit 3 on Day5
Reported as:
Geometric mean · h·ng/mL
Area Under the Concentration-time Curve From 0 to Time to Last Quantifiable Concentration (AUClast) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2 (Day 2), and Visit 3 (Day 5)
h·ng/mLAcalabrutinib + BSC + PPI, Visit 1 on Day 1Acalabrutinib + BSC + PPI, Visit 2 on Day 2Acalabrutinib + BSC + PPI, Visit 3 on Day 5
Acalabrutinib490.1 ± 64.8493.7 ± 58.4193.7 ± 96.6
ACP-5862731.0 ± 38.41228.0 ± 35.1827.9 ± 46.2
PrimaryMaximum Observed Plasma Concentration (Cmax) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2(Day2) and Visit 3 (Day 5)

To summarize the PK parameter Cmax of Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC +PPI

Time frame:
pre-dose and 0.5, 1, 2, 4, 6, and 12 hours in visit 1(Day 1), visit 2(Day 2) and visit 3(Day 5)
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2(Day2) and Visit 3 (Day 5)
ng/mLAcalabrutinib + BSC + PPI, Visit 1 on Day 1Acalabrutinib + BSC + PPI, Visit 2 on Day 2Acalabrutinib + BSC + PPI, Visit 3 on Day 5
Acalabrutinib297.0 ± 56.7307.9 ± 51.3167.1 ± 88.7
ACP-5862213.1 ± 62.9316.9 ± 38.5324.2 ± 47.6

Adverse events

Collected over 2 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acalabrutinib + BSC + PPI2/9 (22.2%)5/9 (55.6%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventAcalabrutinib + BSC + PPI
Pneumonia bacterialInfections and infestations2/9
Device related infectionInfections and infestations1/9
PneumoniaInfections and infestations1/9
Transaminases increasedInvestigations1/9
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/9
HypotensionVascular disorders1/9
Most frequent other events
Showing 10 of 32
Most frequent other events
EventAcalabrutinib + BSC + PPI
AnaemiaBlood and lymphatic system disorders5/9
LymphopeniaBlood and lymphatic system disorders2/9
Abdominal distensionGastrointestinal disorders2/9
PneumoniaInfections and infestations2/9
Pneumonia bacterialInfections and infestations2/9
Alanine aminotransferase increasedInvestigations2/9
Aspartate aminotransferase increasedInvestigations2/9
HypernatraemiaMetabolism and nutrition disorders2/9
HypophosphataemiaMetabolism and nutrition disorders2/9
Peripheral motor neuropathyNervous system disorders2/9

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Acalabrutinib + BSC + PPI
Mean61.3 ± 10.7
Age, Customized
Age, Customized(Participants)Acalabrutinib + BSC + PPI
< 65 years4
>= 65 years5
Sex: Female, Male
Sex: Female, Male(Participants)Acalabrutinib + BSC + PPI
Female4
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Acalabrutinib + BSC + PPI
Hispanic or Latino7
Not Hispanic or Latino2
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Acalabrutinib + BSC + PPI
WHITE7
BLACK OR AFRICAN AMERICAN2
AMERICAN INDIAN OR ALASKA NATIVE0
ASIAN0
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER0
OTHER0
NOT REPORTED0
08

Study locations

4 sites
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    Sao Paulo, 01321-001, Brazil
  • Research Site
    Sao Paulo, 01323-903, Brazil
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Nov 2020, 1 month.

Results were first posted in Nov 2021, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2020
First posted
Aug 4, 2020
StartActual
Sep 21, 2020
Primary completionActual
Nov 18, 2020
CompletionActual
Nov 18, 2020
Results first posted
Nov 5, 2021
Last update
Nov 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04497948
Lead sponsor
Acerta Pharma BV
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Aug 4, 2020
Start date
Sep 21, 2020
Primary completion
Nov 18, 2020
Completion
Nov 18, 2020
Results posted
Nov 5, 2021
Last update
Nov 17, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion